<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-01T17:16:02Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/33829" metadataPrefix="qdc">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/33829</identifier><datestamp>2026-02-03T11:19:10Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><qdc:qualifieddc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to Treat</dc:title>
   <dc:creator>García-Ruiz, Antonio J.</dc:creator>
   <dc:creator>Izquierdo-Ayuso, Guillermo</dc:creator>
   <dc:creator>Navarro-Mascarell, Guillermo</dc:creator>
   <dc:creator>Montesinos-Gálvez, Ana Carmen</dc:creator>
   <dc:creator>Martos-Crespo, Francisco</dc:creator>
   <dc:creator>Jódar-Sánchez, Francisco</dc:creator>
   <dc:creator>Correa, manuel</dc:creator>
   <dc:creator>García-Agua-Soler, Nuria</dc:creator>
   <dc:subject>Esclerosis múltiple</dc:subject>
   <dcterms:abstract>The aim of this study was to analyze the efficacy of drugs used in relapsing-remitting multiple sclerosis, first- and second-line drugs, using the number needed to treat (NNT) as a measure of efficacy.&#xd;
Methods: Data from randomized clinical trials were analyzed for 3 categories of clinical efficacy outcomes: relapse, change in Expanded Disability Status Scale, and number of new lesions in magnetic resonance imaging. Meta-analysis results are expressed as odds ratios.&#xd;
Results: The global odds ratio was 0.41 (95% confidence interval [CI], 0.34-0.49). For analyzed clinical outcomes, the odds ratio was less for second-line drugs (odds ratio, 2.0). For all studied clinical conditions, in the control group, 47 of 100 patients do not get benefits, compared with 25 (95% CI, 18-32 patients) of 100 for the active treatment group. The NNT was 5 patients (95% CI, 4-7 patients). For the proportion of patients free of relapses, in the control group, 56 of 100 patients had a relapse at 2 years, compared with 37 of 100 patients in the treatment group, with an NNT of 6 patients (95% CI, 5-8 patients).&#xd;
Conclusions: Active treatments produced statistically significant improvements compared with placebo.</dcterms:abstract>
   <dcterms:dateAccepted>2024-09-28T11:43:44Z</dcterms:dateAccepted>
   <dcterms:available>2024-09-28T11:43:44Z</dcterms:available>
   <dcterms:created>2024-09-28T11:43:44Z</dcterms:created>
   <dcterms:issued>2017-01</dcterms:issued>
   <dc:type>journal article</dc:type>
   <dc:identifier>García-Ruiz, A. J., Izquierdo-Ayuso, G., Navarro-Mascarell, G., Montesinos-Gálvez, A. C., Martos-Crespo, F., Jódar-Sánchez, F., Correa, M., &amp; García-Agua Soler, N. (2017). Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to Treat. Clinical neuropharmacology, 40(1), 37–42. https://doi.org/10.1097/WNF.0000000000000201</dc:identifier>
   <dc:identifier>https://hdl.handle.net/10630/33829</dc:identifier>
   <dc:identifier>10.1097/WNF.0000000000000201</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:rights>open access</dc:rights>
   <dc:publisher>Lippincott Williams &amp; Wilkins</dc:publisher>
</qdc:qualifieddc>
</metadata></record></GetRecord></OAI-PMH>